Combination of Rosiglitazone and Donepezil for Improvement of Cognitive Function - Patent Disclosed is a pharmaceutical composition comprising both rosiglitazone or a pharmaceutically acceptable salt thereof and donepezil or a pharmaceutically acceptable salt thereof which is of use in the treatment or prophylaxis of Alzheimer's disease or other dementias and mild cognitive impairment. Also disclosed is an oral dosage forms comprising rosiglitazone or a pharmaceutically acceptable salt thereof and donepezil or a pharmaceutically acceptable salt thereof. An oral dosage formulation comprising an erodable core which comprises an oral dosage formulation as claimed in claim 19 and an erodable coating around the core, wherein the erodable coating comprises one or more openings extending substantially completely through said coating but not penetrating the core and communicating from the environment of use to the core, wherein release of the rosiglitazone or a pharmaceutically acceptable salt thereof and donepezil or a pharmaceutically acceptable salt thereof from the core occurs substantially through said opening(s) and through erosion of the coating under pre-determined pH conditions. European Patent 306228 describes a class of PPAR-gamma agonists which are thiazolidinedione derivatives for use as insulin sensitizers in the treatment of Type II diabetes mellitus. These compounds have anti-hyperglycaemic activity. One preferred compound described therein is known by the chemical name 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione and has been given the generic name rosiglitazone. Salts of this compound, including the maleate salt, are described in WO94/05659.
